Cannabis in India: ancient lore and modern medicine

  • Ethan Russo
Part of the Milestones in Drug Therapy MDT book series (MDT)


Premature Ejaculation Ayurvedic Medicine Aversive Memory Cannabis Extract Indian Hemp 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaplan J (1969) Marijuana. Report of the Indian Hemp Drugs Commission, 1893–1894. Thomas Jefferson Publishing Co., Silver Spring, MDGoogle Scholar
  2. 2.
    Merlin MD (2003) Archaeological evidence for the tradition of psychoactive plant use in the Old World. Econ Bot 57: 295–323Google Scholar
  3. 3.
    Nadkarni KM (1976) Indian material medical. Popular Prakashan, BombayGoogle Scholar
  4. 4.
    Kapoor LD (1990) CRC handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton, FLGoogle Scholar
  5. 5.
    Candolle Ad (1883) Origine des plants cultivées. G. Baillière et Cie., ParisGoogle Scholar
  6. 6.
    Candolle Ad (1886) Origin of cultivated plants. Paul Trench, LondonGoogle Scholar
  7. 7.
    de Bunge A (1860) Lettre de M. Alex. de Bunge à M. Decaisne. Botanique de France 7: 29–31Google Scholar
  8. 8.
    Ames O (1939) Economic annuals and human cultures. Botanical Museum of Harvard University, Cambridge, MAGoogle Scholar
  9. 9.
    Fleming MP, Clarke RC (1998) Physical evidence for the antiquity of Cannabis sativa L. J Int Hemp Assoc 5: 280–293Google Scholar
  10. 10.
    Bouquet RJ (1950) Cannabis. Bull Narc 2: 14–30Google Scholar
  11. 11.
    Merlin MD (1972) Man and marijuana; some aspects of their ancient relationship. Fairleigh Dickinson University Press, Rutherford, NJGoogle Scholar
  12. 12.
    Sharma GK (1979) Significance of eco-chemical studies of cannabis. Science and Culture 45: 303–307Google Scholar
  13. 13.
    Sarianidi V (1994) Temples of Bronze Age Margiana: traditions of ritual architecture. Antiquity 68: 388–397Google Scholar
  14. 14.
    Sarianidi V (1998) Margiana and protozoroastrism. Kapon Editions, AthensGoogle Scholar
  15. 15.
    Witzel M (1999) Early sources for South Asian substrate languages. Mother Tongue October: 1–70Google Scholar
  16. 16.
    Darmesteter J (1895) Zend-Avesta, Part I, The Vendidad. Oxford University, LondonGoogle Scholar
  17. 17.
    Mahdihassan S (1982) Etymology of names — ephedra and cannabis. Studies in the History of Medicine 6: 63–66Google Scholar
  18. 18.
    Grierson GA (1894) The hemp plant in Sanskrit and Hindi literature. Indian Antiquary September: 260–262Google Scholar
  19. 19.
    Dwarakanath C (1965) Use of opium and cannabis in the traditional systems of medicine in India. Bull Narc 17: 15–19Google Scholar
  20. 20.
    Sanyal PK (1964) A story of medicine and pharmacy in India: Pharmacy 2000 years ago and after. Shri Amitava Sanyal, CalcuttaGoogle Scholar
  21. 21.
    Watt G (1889) A dictionary of the economic products of India. Superintendent of Government Printing, CalcuttaGoogle Scholar
  22. 22.
    Aldrich MR (1977) Tantric cannabis use in India. J Psychedelic Drugs 9: 227–233Google Scholar
  23. 23.
    Dash VB (1999) Fundamentals of Ayurvedic medicine. Sri Satguru Publications, DelhiGoogle Scholar
  24. 24.
    Rao BR (1971) Anandakandam (root of bliss). A medieval medical treatise of South India. Bulletin of the Intistute of History of Medicine (Hyderabad) 1: 7–9Google Scholar
  25. 25.
    Meulenbeld GJ (1989) The search for clues to the chronology of Sanskrit medical texts as illustrated by the history of bhanga. Studien zur Indologie und Iranistik 15: 59–70Google Scholar
  26. 26.
    Wujastyk D (2002) Cannabis in traditional Indian herbal medicine. In: A Salema (ed.): Ayudveda at the crossroad of care and cure. Universidade Nova, Lisbon, 45–73Google Scholar
  27. 27.
    Dymock W (1884) The vegetable material medical of Western India. Education Society’s Press, BombayGoogle Scholar
  28. 28.
    Sarngadhara, Srikanthamurthy KR (1984) Sarngadhara-samhita: a treatise of Ayurveda. Chaukhambha Orientalia, VaranasiGoogle Scholar
  29. 29.
    Sharma PV (1984) Tantrik influence on Sarngadhara. Ancient Science of Life 3: 129–131Google Scholar
  30. 30.
    Chopra IC, Chopra RW (1957) The use of cannabis drugs in India. Bull Narc 9: 4–29Google Scholar
  31. 31.
    Dash B, Kashyap L, Todaramalla (1980) Materia medical of ayurveda: based on Ayurveda saukhyam of Todarananda. Concept, New DelhiGoogle Scholar
  32. 32.
    da Orta G (1913) Colloquies on the simples and drugs of India. Henry Sotheran, LondonGoogle Scholar
  33. 33.
    O’Shaughnessy WB (1843) On the preparations of the Indian hemp, or gunjah (Cannabis indica). Their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Provincial Medical Journal and Retrospect of the Medical Sciences 5: 343–347, 363–369: 397–398Google Scholar
  34. 34.
    Dymock W, Warden CJH, Hooper D (1890) Pharmacographia indica. A history of the principal drugs of vegetable origin, met with in British India. K. Paul Trench Triibner and Co., LondonGoogle Scholar
  35. 35.
    Ainslie W (1813) Materia medical of Hindoostan, and artisan’s and agriculturist’s nomenclature. Government Press, MadrasGoogle Scholar
  36. 36.
    O’Shaughnessy WB (1838–1840) On the preparations of the Indian hemp, or gunjah (Cannabis indica); Their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of the Medical and Physical Society of Bengal 71–102, 421–461Google Scholar
  37. 37.
    Ley W (1843) Observations on the Cannabis indica, or Indian hemp. Provincial Medical Journal and Retrospect of the Medical Sciences 5: 487–489Google Scholar
  38. 38.
    Clendinning J (1843) Observation on the medicinal properties of Cannabis sativa of India. Medico-Chirurgical Transactions 26: 188–210Google Scholar
  39. 39.
    Shaw J (1843) On the use of the Cannabis indica (or Indian hemp)-lst-in tetanus-2nd-in hydrophobia-3rd-in cholera-with remarks on its effects. Madras Quarterly Medical Journal 5: 74–80Google Scholar
  40. 40.
    Churchill F (1849) Essays on the puerperal fever and other diseases peculiar to women. Selected from the writings of British authors previous to the close of the eighteenth century. Sydenham Society, LondonGoogle Scholar
  41. 41.
    Christison A (1851) On the natural history, action, and uses of Indian hemp. Monthly J Medical Science of Edinburgh, Scotland 13: 26–45: 117–121Google Scholar
  42. 42.
    Russo E (2002) Cannabis treatments in obstetrics and gynecology: A historical review. J Cannabis Therapeutics 2: 5–35CrossRefGoogle Scholar
  43. 43.
    Johnston JFW (1855) The chemistry of common life. D. Appleton, New YorkGoogle Scholar
  44. 44.
    McMeens RR (1860) Report of the Ohio State Medical Committee on Cannabis indica. In: Ohio State Medical Society, White Sulphur Springs, OH, 75–100Google Scholar
  45. 45.
    Dutt UC, Sen BL, Sen A, Sen PK (1980) The material medical of the Hindus. Chowkhamba Saraswatibhawan, VaranasiGoogle Scholar
  46. 46.
    Kerr HC (1893–1894) Report of the cultivation of, and trade in, ganja in Bengal. Birtish Parliamentary Papers 66: 94–154Google Scholar
  47. 47.
    Commission IHD (1894) Report of the Indian Hemp Drugs Commission, 1893–94. Government Central Printing Office, SimlaGoogle Scholar
  48. 48.
    Abel EL (1980) Marihuana, thefirst twelve thousand years. Plenum Press, New YorkGoogle Scholar
  49. 49.
    Mills JH (2000) Madness, cannabis and colonialism: the ‘native only’ lunatic asylums of British India, 1857–1900. St. Martin’s Press, New YorkGoogle Scholar
  50. 50.
    Godley A (1893–1894) Papers relating to the consumption of ganja and other drugs in India. British Parliamentary Papers 66: 1–93Google Scholar
  51. 51.
    Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363: 1579–1588CrossRefPubMedGoogle Scholar
  52. 52.
    Waring EJ (1897) Remarks on the uses of some of the bazaar medicines and common medical plants of India; with a full index of diseases, indicating their treatment by these and other agents procurable throughout India. To which are added directions for treatment in cases of drowning, snake-bite, &c. J. and A. Churchill, LondonGoogle Scholar
  53. 53.
    Khastagir AC (1878) Hemp (ganja) smoking in tetanus on a new principle. Indian Medical Gazette 210–211Google Scholar
  54. 54.
    Lucas JC (1880) Notes on tetanus; with remarks on the efficacy of Cannabis indica when administered through the lungs. Medical Times and Gazette 202–204Google Scholar
  55. 55.
    Du Toit BM (1977) Historical and cultural factors influencing cannabis use among Indians in South Africa. J Psychedelic Drugs 9: 235–246Google Scholar
  56. 56.
    Rubin VD, Comitas L (1975) Ganja in Jamaica: A medical anthropological study of chronic marihuana use. Mouton, The HagueGoogle Scholar
  57. 57.
    Dreher MC (1982) Working men and ganja: marihuana use in rural Jamaica. Institute for the Study of Human Issues, PhiladelphiaGoogle Scholar
  58. 58.
    Ratnam EV (1920) Cannabis indica. J Ceylon Branch of the British Medical Association 17: 36–42Google Scholar
  59. 59.
    Dixon WE (1923) Smoking of Indian hemp and opium. Brit Med J 2: 1179–1180Google Scholar
  60. 60.
    Chopra RN (1940) Use of hemp drugs in India. Indian Medical Gazette 75: 356–367Google Scholar
  61. 61.
    Carstairs GM (1954) Daru and bhang; cultural factors in the choice of intoxicant. Q J Stud Alcohol 15: 220–237PubMedGoogle Scholar
  62. 62.
    Dastur JF (1962) Medicinal plants of India and Pakistan; A concise work describing plants used for drugs and remedies according to Ayurvedic, Unani and Tibbi systems and mentioned in British and American pharmacopoeias. D.B. Taraporevala Sons, BombayGoogle Scholar
  63. 63.
    Karnick CR (1996) Ayurvedic narcotic medicinal plants. Sri Satguru Publications, DelhiGoogle Scholar
  64. 64.
    Clarke RC (1998) Hashish! Red Eye Press, Los AngelesGoogle Scholar
  65. 65.
    Sharma GK (1977) Ethnobotany and its significance for Cannabis studies in the Himalayas. J Psychedelic Drugs 9: 337–339Google Scholar
  66. 66.
    Touw M (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 13: 23–34PubMedGoogle Scholar
  67. 67.
    Chaturvedi GN, Tiwari SK, Rai NP (1981) Medicinal use of opium and cannabis in medieval India. Indian J History of Science 16: 31–25Google Scholar
  68. 68.
    Chopra RN (1982) Chopra’s indigenous drugs of India. Academic Publishers, CalcuttaGoogle Scholar
  69. 69.
    Ghosh P, Bhattacharya SK (1979) Cannabis-induced potentiation of morphine analgesia in rat — role of brain monoamines. Indian J Med Res 70: 275–280PubMedGoogle Scholar
  70. 70.
    Majupuria TC, Joshi DP (1988) Religious and useful plants of Nepal and India. M. Gupta, Lashkar, IndiaGoogle Scholar
  71. 71.
    Manandhar NP, Manandhar S (2002) Plants and people of Nepal. Timber Press, Portland, ORGoogle Scholar
  72. 72.
    Chaturvedi GN, Rai NP, Pandey US, Sing KP, Tiwari SK (1991) Clinical survey of cannabis users in Varanasi. Ancient Science of Life 10: 194–198Google Scholar
  73. 73.
    Gehlot S, Rastogi V, Dubby GP (1996) Role of cannabis extract (tetrahydrocannabinol) for relief of cancer pain. Sachitra Ayurveda 49: 138–140Google Scholar
  74. 74.
    Zuardi AW, Guimaraes FS (1997) Cannabidiol as an anxiolytic and antipsychotic. In: ML Mathre (ed.): Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. McFarland, Jefferson, NC, 133–141Google Scholar
  75. 75.
    Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriat Psychiat 12: 913–919CrossRefGoogle Scholar
  76. 76.
    Deyo RA, Musty RE (2003) A cannabichromene (CBC) extract alters behavioral despair on the mouse tail suspension test of depression. In: 2003 Symposium on the Cannabinoids. International Cannabinoid Research Society, Cornwall, ON, Canada, 146Google Scholar
  77. 77.
    Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534CrossRefPubMedGoogle Scholar
  78. 78.
    Russo EB (2003) Cannabis and cannabis-based medicine extracts: Additional results. J Cannabis Therapeutics 3: 153–162CrossRefGoogle Scholar
  79. 79.
    Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 18–26Google Scholar
  80. 80.
    Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmonds S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 “N of 1” studies. Anaesthesia 59: 440–452CrossRefPubMedGoogle Scholar
  81. 81.
    Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24: 305–313PubMedGoogle Scholar
  82. 82.
    Mikuriya TH (2004) Cannabis as a substitute for alcohol: a harm-reduction approach. J Cannabis Therapeutics 4: 79–93CrossRefGoogle Scholar
  83. 83.
    Dreher M (2002) Crack heads and roots daughters: The therapeutic use of cannabis in Jamaica. J Cannabis Therapeutics 2: 121–133Google Scholar
  84. 84.
    Labigalini E Jr, Rodrigues LR, Da Silveira DX (1999) Therapeutic use of cannabis by crack addicts in Brazil. J Psychoactive Drugs 31: 451–455PubMedGoogle Scholar
  85. 85.
    Mello NK, Mendelson JH (1978) Marihuana, alcohol, and polydrug use: human self-administration studies. NIDA Res Monogr 93–127Google Scholar
  86. 86.
    Mello NK, Mendelson JH, Kuehnle JC, Sellers ML (1978) Human polydrug use: marihuana and alcohol. J Pharmacol Exp Ther 207: 922–935PubMedGoogle Scholar
  87. 87.
    Richardson JD, Aanonsen L, Hargreaves KM (1998) Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345: 145–153CrossRefPubMedGoogle Scholar
  88. 88.
    Russo EB (2004) Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 25: 31–39CrossRefPubMedGoogle Scholar
  89. 89.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526CrossRefPubMedGoogle Scholar
  90. 90.
    Metz L, Page S (2003) Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet 362: 1513CrossRefPubMedGoogle Scholar
  91. 91.
    Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (™)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268–8273Google Scholar
  92. 92.
    Russo E (1998) Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain 76: 3–8CrossRefPubMedGoogle Scholar
  93. 93.
    Russo EB (2001) Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Therapeutics 1: 21–92CrossRefGoogle Scholar
  94. 94.
    Mechoulam R (1986) The pharmacohistory of Cannabis sativa. In: R Mechoulam (ed.): Cannabinoids as therapeutic agents. CRC Press, Boca Raton, FL, 1–19Google Scholar
  95. 95.
    Carlini EA, Cunha JM (1981) Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21: 417S–427SPubMedGoogle Scholar
  96. 96.
    Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307: 129–137CrossRefPubMedGoogle Scholar
  97. 97.
    Wallace MJ, Martin BR, DeLorenzo RJ (2002) Evidence for a physiological role of endo-cannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452: 295–301CrossRefPubMedGoogle Scholar
  98. 98.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022CrossRefPubMedGoogle Scholar
  99. 99.
    Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in marine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561–9566CrossRefPubMedGoogle Scholar
  100. 100.
    Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111–119CrossRefPubMedGoogle Scholar
  101. 101.
    Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benewitz NL, Bredt BM, Kosel B, Aberg JA et al. (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placbo-controlled clinical trial. Ann Intern Med 139: 258–266PubMedGoogle Scholar
  102. 102.
    Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56: 2097–2102CrossRefPubMedGoogle Scholar
  103. 103.
    Musty RE, Rossi R (2001) Effects of smoked cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Therapeutics 1: 29–42CrossRefGoogle Scholar
  104. 104.
    Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745–755CrossRefPubMedGoogle Scholar
  105. 105.
    Maccarrone M, Finazzi-Agro A (2003) The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 10: 946–955CrossRefPubMedGoogle Scholar
  106. 106.
    De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95: 8375–8380CrossRefPubMedGoogle Scholar
  107. 107.
    Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O (2001) Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24: 339–344PubMedGoogle Scholar
  108. 108.
    Williams SJ, Hartley JP, Graham JD (1976) Bronchodilator effect of deltal-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31: 720–723PubMedGoogle Scholar
  109. 109.
    Falk AA, Hagberg MT, Lof AE, Wigaeus-Hjelm EM, Wang ZP (1990) Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation. Scand J Work Environ Health 16: 372–378PubMedGoogle Scholar
  110. 110.
    Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101–121CrossRefPubMedGoogle Scholar
  111. 111.
    McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Therapeutics 1: 103–132CrossRefGoogle Scholar
  112. 112.
    Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48: 859–867CrossRefPubMedGoogle Scholar
  113. 113.
    Wright K, Rooney N, Tate J, Feeney M, Robertson D, Welham M, Ward S (2003) Functional cannabinoid receptor expression in human colonic epithelium. In: 2003 Symposium on the Cannabinoids. International Cannabinoid Research Society, Cornwall, ON, Canada, 25Google Scholar
  114. 114.
    Douthwaite AH (1947) Choice of drugs in the treatment of duodenal ulcer. Brit Med J 2: 43–47Google Scholar
  115. 115.
    Tambe Y, Tsujiuchi H, Honda G, Ikeshiro Y, Tanaka S (1996) Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med 62: 469–470PubMedGoogle Scholar
  116. 116.
    Schnelle M, Grotenhermen F, Reif M, Gorter RW (1999) [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. Forsch Komplementarmed 6(suppl 3): 28–36CrossRefGoogle Scholar
  117. 117.
    Thompson LS (1972) Cannabis sativa and traditions associated with it. Kentucky Folklore Record 18: 1–4Google Scholar
  118. 118.
    Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004) An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 10: 425–433CrossRefPubMedGoogle Scholar
  119. 119.
    Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S (2002) Medicinal cannabis extract in chronic pain: (7) Results from long term safety extension study (CBME-SAFEX). J Cannabis Therapeutics 2: 99–100Google Scholar
  120. 120.
    Ferrari F, Ottani A, Giuliani D (2000) Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. Physiol Behav 69: 547–554CrossRefPubMedGoogle Scholar
  121. 121.
    Kabelik J, Krejčí Z, Santavý F (1960) Cannabis as a medicament. Bull Narc 12: 5–23Google Scholar
  122. 122.
    Blevins RD, Dumic MP (1980) The effect of delta-9-tetrahydrocannabinol on herpes simplex virus replication. J Gen Virol 49: 427–431PubMedGoogle Scholar
  123. 123.
    Campbell WE, Gammon DW, Smith P, Abrahams M, Purves TD (1997) Composition and antimalarial activity in vitro of the essential oil of Tetradenia riparia. Planta Med 63: 270–272PubMedGoogle Scholar
  124. 124.
    ElSohly HN, Turner CE, Clark AM, Eisohly MA (1982) Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 71: 1319–1323PubMedGoogle Scholar
  125. 125.
    Carson CF, Riley TV (1995) Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol 78: 264–269PubMedGoogle Scholar
  126. 126.
    Downs AM, Stafford KA, Coles GC (2000) Monoterpenoids and tetralin as pediculocides. Acta Derm. Venereology 80: 69–70CrossRefGoogle Scholar
  127. 127.
    Enan E (2001) Insecticidal activity of essential oils: octopaminergic sites of action. Comp Biochem Physiol C Toxicol Pharmacol 130: 325–337CrossRefPubMedGoogle Scholar
  128. 128.
    Priestley CM, Williamson EM, Wafford KA, Sattelle DB (2003) Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA-A receptors and a homo-oligomeric GABA receptor form Drosophila melanogaster. Brit J Pharmacol 140: 1363–1372CrossRefGoogle Scholar
  129. 129.
    McPartland JM, Clarke RC, Watson DP (2000) Hemp diseases and pests: Management and biological control. CABI, Wallingford, UKGoogle Scholar
  130. 130.
    Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949PubMedGoogle Scholar
  131. 131.
    Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020–1024CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Ethan Russo
    • 1
  1. 1.GW PharmaceuticalsMissoulaUSA

Personalised recommendations